About Larimar Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://larimartx.com/
Frequently Asked Questions
What is the 52-week range for LRMR?
The 52-week high is $6.42 and the 52-week low is $2.715.
What is the P/E ratio for LRMR?
The P/E ratio data is currently unavailable.
What is the dividend yield for LRMR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -137.39%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.18.
Analyst Recommendation Trends
Wall Street analyst consensus for LRMR over the last few months:
Latest LRMR News
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development ex
Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29
Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Century Therapeutics Appoints Joseph Truitt to Board of Directors
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-29 | Harlow John B. Jr. | +800,000 | - | - |
| 2026-09-29 | Harlow John B. Jr. | +50,000 | - | - |
| 2026-07-06 | Hamilton Thomas Edward | +50,000 | $3.3378 | $166,890 |
| 2026-05-19 | Truitt Joseph | +55,150 | - | - |
| 2026-05-19 | Hamilton Thomas Edward | +55,150 | - | - |
| 2026-05-19 | THOMAS FRANK E | +55,150 | - | - |
| 2026-05-19 | SHERMAN JEFFREY W | +55,150 | - | - |
| 2026-05-19 | LEFF JONATHAN S | +55,150 | - | - |
| 2026-05-19 | DEERFIELD MANAGEMENT COMPANY, L.P. | +55,150 | - | - |
| 2026-02-27 | THOMAS FRANK E | +5,000 | $5 | $25,000 |
| 2026-02-27 | SHERMAN JEFFREY W | +5,000 | $5 | $25,000 |
| 2026-02-27 | Hamilton Thomas Edward | +100,000 | $5 | $500,000 |
| 2026-02-27 | DEERFIELD MANAGEMENT COMPANY, L.P. | +2,000,000 | $5 | $10,000,000 |
| 2026-02-27 | DEERFIELD MANAGEMENT COMPANY, L.P. | +831,978 | $5 | $4,159,890 |
| 2026-02-27 | DEERFIELD MANAGEMENT COMPANY, L.P. | +1,084,012 | $5 | $5,420,060 |
| 2026-02-27 | DEERFIELD MANAGEMENT COMPANY, L.P. | +1,084,010 | $5 | $5,420,050 |
| 2026-01-26 | Shankar Gopi | +153,822 | - | - |
| 2026-01-26 | Shankar Gopi | +25,637 | - | - |
| 2026-01-26 | Clayton Russell | +153,822 | - | - |
| 2026-01-26 | Clayton Russell | +25,637 | - | - |
| 2026-01-26 | BEN-MAIMON CAROLE | +600,600 | - | - |
| 2026-01-26 | BEN-MAIMON CAROLE | +100,100 | - | - |
| 2026-01-26 | Celano Michael | +225,622 | - | - |
| 2026-01-26 | Celano Michael | +37,604 | - | - |